208 related articles for article (PubMed ID: 20831818)
1. Evaluation of multicomponent recombinant vaccines against Actinobacillus pleuropneumoniae in mice.
Shao M; Wang Y; Wang C; Guo Y; Peng Y; Liu J; Li G; Liu H; Liu S
Acta Vet Scand; 2010 Sep; 52(1):52. PubMed ID: 20831818
[TBL] [Abstract][Full Text] [Related]
2. Positive role for rApxIVN in the immune protection of pigs against infection by Actinobacillus pleuropneumoniae.
Wang C; Wang Y; Shao M; Si W; Liu H; Chang Y; Peng W; Kong X; Liu S
Vaccine; 2009 Sep; 27(42):5816-21. PubMed ID: 19654060
[TBL] [Abstract][Full Text] [Related]
3. Recombinant ApxIV protein enhances protective efficacy against Actinobacillus pleuropneumoniae in mice and pigs.
Wu HC; Yeh PH; Hsueh KJ; Yang WJ; Chu CY
J Appl Microbiol; 2018 Jun; 124(6):1366-1376. PubMed ID: 29431246
[TBL] [Abstract][Full Text] [Related]
4. An evaluation of the role of antibodies to Actinobacillus pleuropneumoniae serovar 1 and 15 in the protection provided by sub-unit and live streptomycin-dependent pleuropneumonia vaccines.
Tumamao JQ; Bowles RE; van den Bosch H; Klaasen HL; Fenwick BW; Blackall PJ
Aust Vet J; 2004 Dec; 82(12):773-80. PubMed ID: 15648941
[TBL] [Abstract][Full Text] [Related]
5. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs.
Shin MK; Kang ML; Jung MH; Cha SB; Lee WJ; Kim JM; Kim DH; Yoo HS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):132-9. PubMed ID: 23206402
[TBL] [Abstract][Full Text] [Related]
6. New trends in innovative vaccine development against Actinobacillus pleuropneumoniae.
Loera-Muro A; Angulo C
Vet Microbiol; 2018 Apr; 217():66-75. PubMed ID: 29615259
[TBL] [Abstract][Full Text] [Related]
7. Nasal immunization with major epitope-containing ApxIIA toxin fragment induces protective immunity against challenge infection with Actinobacillus pleuropneumoniae in a murine model.
Seo KW; Kim SH; Park J; Son Y; Yoo HS; Lee KY; Jang YS
Vet Immunol Immunopathol; 2013 Jan; 151(1-2):102-12. PubMed ID: 23200821
[TBL] [Abstract][Full Text] [Related]
8. Cross-protection between Actinobacillus pleuropneumoniae biotypes-serotypes in pigs.
Haesebrouk F; Van de Kerkhof A; Dom P; Chiers K; Ducatelle R
Vet Microbiol; 1996 Oct; 52(3-4):277-84. PubMed ID: 8972053
[TBL] [Abstract][Full Text] [Related]
9. Use of recombinant ApxIV in serodiagnosis of Actinobacillus pleuropneumoniae infections, development and prevalidation of the ApxIV ELISA.
Dreyfus A; Schaller A; Nivollet S; Segers RP; Kobisch M; Mieli L; Soerensen V; Hüssy D; Miserez R; Zimmermann W; Inderbitzin F; Frey J
Vet Microbiol; 2004 Apr; 99(3-4):227-38. PubMed ID: 15066725
[TBL] [Abstract][Full Text] [Related]
10. Type IV fimbrial subunit protein ApfA contributes to protection against porcine pleuropneumonia.
Sadilkova L; Nepereny J; Vrzal V; Sebo P; Osicka R
Vet Res; 2012 Jan; 43(1):2. PubMed ID: 22240397
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous detection of antibodies against Apx toxins ApxI, ApxII, ApxIII, and ApxIV in pigs with known and unknown Actinobacillus pleuropneumoniae exposure using a multiplexing liquid array platform.
Giménez-Lirola LG; Jiang YH; Sun D; Hoang H; Yoon KJ; Halbur PG; Opriessnig T
Clin Vaccine Immunol; 2014 Jan; 21(1):85-95. PubMed ID: 24226091
[TBL] [Abstract][Full Text] [Related]
12. Identification of proteins of Propionibacterium acnes for use as vaccine candidates to prevent infection by the pig pathogen Actinobacillus pleuropneumoniae.
Li L; Sun C; Yang F; Yang S; Feng X; Gu J; Han W; Langford PR; Lei L
Vaccine; 2013 Oct; 31(45):5269-75. PubMed ID: 24051157
[TBL] [Abstract][Full Text] [Related]
13. DNA vaccine encoding type IV pilin of Actinobacillus pleuropneumoniae induces strong immune response but confers limited protective efficacy against serotype 2 challenge.
Lu YC; Li MC; Chen YM; Chu CY; Lin SF; Yang WJ
Vaccine; 2011 Oct; 29(44):7740-6. PubMed ID: 21835218
[TBL] [Abstract][Full Text] [Related]
14. Interference of outer membrane protein PalA with protective immunity against Actinobacillus pleuropneumoniae infections in vaccinated pigs.
van den Bosch H; Frey J
Vaccine; 2003 Sep; 21(25-26):3601-7. PubMed ID: 12922088
[TBL] [Abstract][Full Text] [Related]
15. Galactose-1-phosphate uridyltransferase (GalT), an in vivo-induced antigen of Actinobacillus pleuropneumoniae serovar 5b strain L20, provided immunoprotection against serovar 1 strain MS71.
Zhang F; Zhao Q; Quan K; Zhu Z; Yang Y; Wen X; Chang YF; Huang X; Wu R; Wen Y; Yan Q; Huang Y; Ma X; Han X; Cao S
PLoS One; 2018; 13(6):e0198207. PubMed ID: 29856812
[TBL] [Abstract][Full Text] [Related]
16. Characterization and immunogenicity of an apxIA mutant of Actinobacillus pleuropneumoniae.
Xu F; Chen X; Shi A; Yang B; Wang J; Li Y; Guo X; Blackall PJ; Yang H
Vet Microbiol; 2006 Dec; 118(3-4):230-9. PubMed ID: 16930871
[TBL] [Abstract][Full Text] [Related]
17. Nasal immunization with M cell-targeting ligand-conjugated ApxIIA toxin fragment induces protective immunity against Actinobacillus pleuropneumoniae infection in a murine model.
Park J; Seo KW; Kim SH; Lee HY; Kim B; Lim CW; Kim JH; Yoo HS; Jang YS
Vet Microbiol; 2015 May; 177(1-2):142-53. PubMed ID: 25818577
[TBL] [Abstract][Full Text] [Related]
18. Development of a DIVA subunit vaccine against Actinobacillus pleuropneumoniae infection.
Maas A; Meens J; Baltes N; Hennig-Pauka I; Gerlach GF
Vaccine; 2006 Nov; 24(49-50):7226-37. PubMed ID: 17027123
[TBL] [Abstract][Full Text] [Related]
19. In vivo testing of novel vaccine prototypes against Actinobacillus pleuropneumoniae.
Antenucci F; Fougeroux C; Deeney A; Ørskov C; Rycroft A; Holst PJ; Bojesen AM
Vet Res; 2018 Jan; 49(1):4. PubMed ID: 29316978
[TBL] [Abstract][Full Text] [Related]
20. Protective efficacy of an affinity-purified hemolysin vaccine against experimental swine pleuropneumonia.
Haga Y; Ogino S; Ohashi S; Ajito T; Hashimoto K; Sawada T
J Vet Med Sci; 1997 Feb; 59(2):115-20. PubMed ID: 9070983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
